Drugs Made In America Acquisition II Corp. (DMIIU) Enterprise Value (2024 - 2025)
Drugs Made In America Acquisition (DMIIU) posted quarterly Enterprise Value of -$223.0 for Q4 2025, up 98.69% year-over-year from -$112.23 in Q4 2024, and up 99.93% quarter-over-quarter from -$315087.0 in Q3 2025.
Drugs Made In America Acquisition II Corp. (DMIIU) Enterprise Value (2024 - 2025) Analysis & Trends
Drugs Made In America Acquisition (DMIIU) has reported Enterprise Value for 2 consecutive years, with -$223.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Enterprise Value rose 98.69% year-over-year to -$223.0; the TTM figure through Dec 2025 stood at -$223.0 (up 98.69% YoY), while the FY2025 annual figure was -$223.0, up 98.69% from the prior year.
- Enterprise Value climbed to -$223.0 in Q4 2025 per DMIIU's latest filing, from -$315087.0 in the prior quarter.
- Across five years, Enterprise Value topped out at -$223.0 in Q4 2025 and bottomed at -$315087.0 in Q3 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -223.00 |
| Sep 30, 2025 | -315,087.00 |
| Dec 31, 2024 | -17,035.00 |